Key result
Balloon aortic valvuloplasty reduced the proportion of patients with Class IV congestive heart failure from 60.7% at baseline to 15.4%, improving candidacy for TAVR.
Why the study?
Does balloon aortic valvuloplasty improve frailty measures and NYHA class in inoperable or high-risk patients with critical aortic stenosis?
Cohort (n=117)
Does balloon aortic valvuloplasty improve frailty measures and NYHA class in inoperable or high-risk patients with critical aortic stenosis?
Balloon aortic valvuloplasty improves functional status and heart failure symptoms in high-risk patients with critical aortic stenosis, facilitating subsequent definitive valve therapy in the majority of cases.
Answers are grounded in this paper and cite their sources.
May improve TAVR candidacy in Class IV HF; hypothesis-generating and requires prospective validation.
OBJECTIVES: Evaluate the role of balloon aortic valvuloplasty (BAV) in improving candidacy of patients for transcatheter aortic valve replacement (TAVR). BACKGROUND: Patients who are not candidates for TAVR may undergo BAV to improve functional and clinical status. METHODS: 117 inoperable or high-risk patients with critical aortic stenosis underwent BAV as a bridge-to-decision for TAVR. Frailty measures including gait speed, serum albumin, hand grip, activities of daily living (ADL); and NYHA functional class before and after BAV were compared. RESULTS: Mean age was 81.6 ± 8.5 years and the mean Society of Thoracic Surgeons predicted risk of mortality was 9.57 ± 5.51, with 19/117 (16.2%) patients non-ambulatory. There was no significant change in mean GS post-BAV, but all non-ambulatory patients completed GS testing at follow-up. Albumin and hand grip did not change after BAV, but there was a significant improvement in mean ADL score (4.85 ± 1.41 baseline to 5.20 ± 1.17, P = 0.021). The number of patients with Class IV congestive heart failure (CHF) was significantly lower post BAV (71/117 [60.7%] baseline versus 18/117 [15.4%], P = 0.008). 78/117 (66.7%) of patients were referred to definitive valve therapy after BAV. CONCLUSIONS: When evaluating frailty measures post BAV, we saw no significant improvement in mean GS, however, we observed a significant improvement in non-ambulatory patients and ADL scores. We also describe improved Class IV CHF symptoms. With this improved health status, the majority of patients underwent subsequent valve therapy, demonstrating that BAV may improve candidacy of patients for TAVR.
No takes yet. Share an insight, caveat, or question.
Arsalan et al. (2017) conducted a cohort in Critical aortic stenosis (n=117). Balloon aortic valvuloplasty (BAV) vs. Baseline (pre-BAV) was evaluated on Class IV congestive heart failure (CHF) (p=0.008). Balloon aortic valvuloplasty reduced the proportion of patients with Class IV congestive heart failure from 60.7% at baseline to 15.4%, improving candidacy for TAVR.
Synapse has enriched 10 related papers. Consider them for comparative context: